|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:J05AE03
|
|
gptkbp:bioavailability
|
75%
|
|
gptkbp:blackBoxWarning
|
true
|
|
gptkbp:CASNumber
|
gptkb:155213-67-5
|
|
gptkbp:contraindication
|
severe hepatic impairment
concomitant use with certain drugs (e.g., amiodarone, simvastatin)
|
|
gptkbp:drugClass
|
antiretroviral agent
|
|
gptkbp:eliminatedIn
|
renal
fecal
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:halfLife
|
3-5 hours
|
|
gptkbp:hasBiologicalActivity
|
HIV-1 protease IC50 = 0.022 μM
|
|
gptkbp:hasBoxedWarning
|
co-administration with certain drugs may cause serious or life-threatening reactions
|
|
gptkbp:hasInChIKey
|
XJXATXUYYNQJNS-GMSGPILRSA-N
|
|
gptkbp:hasMolecularFormula
|
C37H48N6O5S2
|
|
gptkbp:hasPharmacokinetics
|
inhibits CYP2D6
inhibits CYP3A4
|
|
gptkbp:hasSMILES
|
CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
|
|
gptkbp:hasUNII
|
QZJ8J8U5F4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL3529
|
|
gptkbp:indication
|
HIV infection
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isUsedInCombinationWith
|
gptkb:lopinavir
|
|
gptkbp:legalStatus
|
expired
Prescription only
|
|
gptkbp:manufacturer
|
gptkb:AbbVie
|
|
gptkbp:mechanismOfAction
|
HIV protease inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
720.95
|
|
gptkbp:name
|
gptkb:Ritonavir
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
98-99%
|
|
gptkbp:PubChem_CID
|
392622
DB00503
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
hepatotoxicity
lipodystrophy
|
|
gptkbp:synonym
|
gptkb:Norvir
gptkb:ABT-538
|
|
gptkbp:target
|
HIV-1 protease
|
|
gptkbp:therapeuticArea
|
antiviral
|
|
gptkbp:bfsParent
|
gptkb:Oxytocin
gptkb:oxytocin
|
|
gptkbp:bfsLayer
|
7
|